Dipharma Takes Full Control of UK Rare Disease Unit
Suppliers and homecare providers in the UK rare disease market should expect LogixX to become a launch platform for Dipharma products.
Updated on Nov. 6, 2026 in Healthcare

Dipharma has completed its acquisition of UK-based LogixX Pharma, which becomes a wholly owned subsidiary of the Dipharma Group. The deal gives Dipharma a direct commercial presence in the UK rare and metabolic disease market, and the company's fertility business was excluded from the transaction.
Why it matters
The acquisition converts a nearly decade-long distribution partnership into direct ownership, giving Dipharma a platform for future UK product launches. For healthcare suppliers, it signals consolidation in the market for rare and metabolic medicines that serve the NHS and homecare providers.
LogixX, founded in 2010, has served as Dipharma's UK commercial partner for nearly ten years and has distributed sapropterin dihydrochloride since 2023. The announcement disclosed no deal value and no revenue or market-share comparators.
The players
Dipharma Group
Swiss-headquartered pharmaceutical group focused on developing and commercializing medicines, including treatments for rare chronic diseases.
LogixX Pharma
UK specialty pharmaceutical company headquartered in Theale, Berkshire, that markets medicines for rare and metabolic diseases to the NHS and homecare providers.
The details
Under the completed deal, LogixX becomes a wholly owned subsidiary of Dipharma and keeps its existing name and leadership under Michael Close, with employees remaining in their current roles. The structure moves LogixX from an arm's-length distribution relationship into the parent group, which can simplify product launches and portfolio planning. LogixX's fertility business, now operating as a separate company, was excluded from the transaction.
Timeline
LogixX became Dipharma's UK commercial partner nearly ten years before the acquisition.
LogixX was founded in 2010.
LogixX began distributing sapropterin dihydrochloride for Dipharma in 2023.
The acquisition completion was reported on 6 November 2026.
Market Landscape
The transaction brings a long-standing distribution partner fully inside the Dipharma Group, a pattern in which pharmaceutical parents internalize proven regional commercial operations. It places the deal among moves to strengthen direct control of niche UK rare disease channels rather than relying on third-party distributors.
Suppliers and homecare providers working with LogixX should expect continuity under its current leadership, with employees remaining in their roles. Procurement teams in the rare disease segment should monitor whether the parent's product launches begin routing through LogixX, which could change contract terms.
The takeaway
Distribution partners in specialty pharma may be absorbed into parent companies once their performance is established, so vendors should review contract assignment and change-of-control terms. Watch for announced UK product launches from Dipharma that would show how the integrated platform is used.
Further reading
For broader context on how drug makers are reshaping their distribution networks, see the Healthcare section.
Source note: This article includes information reported by Manufacturingchemist.


